What is claimed is:

1. A compound of Formula (I)

5

or pharmaceutically acceptable salt or solvate thereof

wherein

A¹ and A² are each independently C₁₋₄alkylene or a bond;

10 A^3 is a bond, C_{1-4} alkylene or C_{1-4} alkylidene;

 A^4 is C_{1-4} alkylene or a bond and is attached to X, X^1 or X^2 ;

X, X¹, X² and X³ are independently C or CH;

J is C₁₄alkyl;

p is 0 or 1;

15

 R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O- C_{1-4} alkyl or C_{1-4} alkyl-N(H)C(O)O-;

said C_{3-6} cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy, indolyl or halo;

20

wherein said indolyl is optionally substituted by halo or cyano;

	or are independently selected from the group of heterocyclic
	moieties consisting of thienyl, furanyl, pyrrolyl,
	pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl,
	imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl,
5	pyridyl, pyrimidinyl, piperidinyl, piperazinyl,
	morpholino, adamantyl, indolyl, isoindolyl, indolinyl,
	quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl,
	isoquinolinyl, dihydroisoquinolinyl and
	tetrahydroisoquinolinyl, wherein said heterocyclic
10	moieties are optionally substituted with halo, C ₁₋₄ alkyl,
	C ₁₋₄ alkoxy or cyano;
	or wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to
	which they are attached form pyrrolyl, pyrrolinyl,
	pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl,
15	pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl,
	pyrimidinyl, piperidinyl, piperazinyl, morpholino,
	indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl,
	dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl,
	dihydroisoquinolinyl or tetrahydroisoquinolinyl and are
20	optionally substituted with halo, C ₁₋₄ alkyl, C ₁₋₄ alkoxy,
	cyano or benzyl;
	R ³ is H or C ₁₋₄ alkyl;
	m is 0 or 1;
	R ⁴ and R ⁵ are independently hydrogen, cyano, halo, nitro, C ₁₋₃ alkyl or
25	C ₁₋₃ perfluoroalkyl;
	wherein said R^4 or R^5 may be independently attached to G^1 , X , X^1 , X^2 or X^3 ;
	n is 0 or 1;
	G is N, O or S;
30	G ¹ is N, C or CH;

Y is (D)H wherein D is C; and Z is (E)H wherein E is C; provided that both R⁴ and R⁵ are not attached to the same of said G¹, X, X¹, X^2 or X^3 ; 5 if G is O or S, then m is 0; if G is N, then m is 1; if R₁ is C₃₋₆cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C₁₋₄alkyl, 10 C_{1-3} alkoxy, indolyl or halo; wherein said indolyl is optionally substituted by halo or cyano, then R₂ is H or C_{1-3} alkyl; if R₂ is C₃₋₆cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C₁₋₄alkyl, C₁₋₃alkoxy, indolyl or halo; wherein said indolyl is 15 optionally substituted by halo or cyano, then R₁ is H or C₁₋₃alkyl; if -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached form pyrrolyl, pyrrolinyl, pyrrolidinyl, 20 imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, 25 dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy, cyano or benzyl, then p is 0; if R1 is -N(H)C(O)OC14alkyl, C14alkyl-N(H)C(O)O- or said

heterocyclic moiety wherein said heterocyclic moiety

	contains a nitrogen atom and said nitrogen atom is attached to A^1 , then A^1 is C_{2-4} alkylene;
5	if R^2 is -N(H)C(O)OC ₁₋₄ alkyl, C ₁₋₄ alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^2 , then A^2 is C ₂₋₄ alkylene;
	if R ¹ is N(H)C(O)O-C ₁₋₄ alkyl, C ₁₋₄ alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl,
10	imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl,
15	dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4} alkyl, C_{1-4} alkoxy or cyano, then R^2 is H or C_{1-3} alkyl;
20	if R ² is -N(H)C(O)O-C ₁₋₄ alkyl, C ₁₋₄ alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl,
25	indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C ₁₋₄ alkyl, C ₁₋₄ alkoxy or cyano,
30	then R^1 is H or C_{1-3} alkyl; if R^4 or R^5 are attached to G^1 , then G^1 is C ;

if A^4 , R^4 or R^5 are attached to X, then X is C; if A^4 , R^4 or R^5 are attached to X^1 , then X^1 is C; if A^4 , R^4 or R^5 are attached to X^2 , then X^2 is C; if R^4 or R^5 are attached to X^3 , then X^3 is C.

5

15

- 2. A compound according to claim 1 wherein p is 0.
- 3. A compound according to claim 1 wherein G is N and G¹ is CH.
- 4. A compound according to claim 1 wherein G is S and G¹ is CH.
- 5. A compound according to claim 1 wherein G is N and G¹ is N.
- 10 6. A compound according to claim 1 wherein G is S and G¹ is N.
 - 7. A compound according to claim 1 wherein G is O and G¹ is N.
 - 8. A compound according to claim 1 wherein R^1 is methyl and R^2 is methyl.
 - 9. A compound according to claim 1 wherein R¹ is H and R² is C₃₋₆cycloalkyl wherein said C₃₋₆cycloalkyl is substituted with indolyl and wherein said indolyl is optionally substituted by halo or cyano.
 - 10. A compound according to claim 1 wherein A^1 is a bond, R^1 is methyl, A^2 is a bond and R^2 is methyl.
 - 11. A compound according to claim 1 wherein R¹ and R² are independently H, C₁₋₃alkyl, C₃₋₆cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O-C₁₋₄alkyl or C₁₋₄alkyl-
- N(H)C(O)O-; said C₃₋₆cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C₁₋₄alkyl, C₁₋₃alkoxy or halo.
 - 12. A compound according to claim 1 wherein R^1 and R^2 are independently H, C_{1-3} alkyl, phenyl, said phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy or halo.
- 25 13. A compound according to claim 1 wherein R¹ and R² are independently H or unsubstituted C₁₋₃alkyl or phenyl.
 - 14. A compound according to claim 1 wherein R^1 and R^2 are independently H or unsubstituted C_{1-3} alkyl or phenyl and A^1 and A^2 are independently C_{1-4} alkylene.
- 15. A compound according to claim 1 wherein -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached form pyrrolyl, pyrrolinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl,

10

25

- dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C_{1-4} alkyl, C_{1-4} alkoxy, cyano or benzyl.
- 16. A compound according to claim 1 wherein -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached form unsubstituted pyrrolyl, pyrrolinyl,
- 5 pyrrolidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolinyl, isoindolyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl.
 - 17. A compound according to claim 1 wherein -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached form unsubstituted pyrrolidinyl, piperidinyl, morpholino or isoindolinyl.
 - 18. A compound according to claim 1 wherein R³ is H and m is 1.
 - 19. A compound according to claim 1 wherein n is 0.
 - 20. A compound according to claim 1 wherein R⁴ and R⁵ are halo.
 - 21. A compound according to claim 1 wherein R^4 is C_{1-3} alkyl and is attached to G^1 .
- 22. A compound according to claim 1 wherein R⁴ is C₁₋₃perfluoroalkyl and is attached to G¹.
 - 23. A compound according to claim 1 wherein R⁴ is hydrogen.
 - 24. A compound according to claim 1 wherein R⁴ is fluoro.
 - 25. A compound according to claim 1 wherein R⁴ is cyano.
- 20 26. A compound according to claim 1 wherein R⁴ is cyano or fluoro.
 - 27. A compound according to claim 1 wherein R⁴ and R⁵ are each fluoro.
 - 28. A compound according to claim 1 wherein the hydrogen atom attached to D is in the *trans* configuration to the hydrogen atom attached to E.
 - 29. A compound according to claim 1 wherein the hydrogen atom attached to D is in the *cis* configuration to the hydrogen atom attached to E.
 - 30. A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to which it is attached has an absolute configuration of S.
- 31. A compound according to claim 1 wherein D in relation to the four moieties to30 which it is attached has an absolute configuration of S; E in relation to the four moieties to which it is attached has an absolute configuration of R.

	32. A compound according to claim 1 wherein D in relation to the four moieties to		
which it is attached has an absolute configuration of R; E in relation to the			
	moieties to which it is attached has an absolute configuration of S.		
33. A compound according to claim 1 wherein D in relation to the four moie			
	which it is attached has an absolute configuration of R; E in relation to the four		
	moieties to which it is attached has an absolute configuration of R.		
	34. A compound according to claim 1 wherein A ³ is a bond.		
	35. A compound according to claim 1 wherein A ³ is C ₁₋₄ alkylene.		
	36. A compound according to claim 1 wherein A ³ is C ₁₋₄ alkylidene.		
	37. A compound according to claim 1 wherein A ³ is methylene.		
	38. A compound according to claim 1 wherein A ⁴ is a bond.		
	39. A compound according to claim 1 wherein A ⁴ is methylene.		
	40. A compound according to claim 1 wherein A ⁴ is attached X ¹ .		
	41. A compound according to claim 1 wherein A ⁴ is attached X.		
	42. A compound according to claim 1 wherein R ⁴ is attached X.		
43. A compound according to claim 1 wherein			
	A^1 and A^2 are each independently C_{1-4} alkylene or a bond;		
	A ³ is a bond;		
	A^4 is a bond and is attached to X^1 ;		
	X and X ¹ are each C;		
	X^2 and X^3 are each CH;		
	p is 0;		
	R ¹ and R ² are independently H, C ₁₋₃ alkyl, C ₃₋₆ cycloalkyl, phenyl, -O		
	phenyl, -N(H)C(O)O-C ₁₋₄ alkyl or C ₁₋₄ alkyl-N(H)C(O)O-;		
	said C ₃₋₆ cycloalkyl, phenyl or O-phenyl being		
	independently and optionally substituted with		
	C ₁₋₄ alkyl, C ₁₋₃ alkoxy or halo;		

or are independently selected from the group of heterocyclic

moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl,

imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, 5 isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoguinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano; or wherein -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached form pyrrolyl, pyrrolinyl, 10 pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl, 15 dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy, cyano or benzyl; R³ is H; 20 m is 1; R⁴ is hydrogen, cyano, halo, nitro, C₁₋₃alkyl or C₁₋₃perfluoroalkyl and is attached to X; n is 0; G is N; G¹ is CH; 25 Y is (D)H wherein D is C; and Z is (E)H wherein E is C;

provided that

	if R ¹ is -N(H)C(O)OC ₁₋₄ alkyl, C ₁₋₄ alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A ¹ , then A ¹ is C ₂₋₄ alkylene;
5	if R ² is -N(H)C(O)OC ₁₋₄ alkyl, C ₁₋₄ alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A ² , then A ² is C ₂₋₄ alkylene;
10	if R ¹ is N(H)C(O)O-C ₁₋₄ alkyl, C ₁₋₄ alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl,
15	piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally
20	substituted with halo, C ₁₋₄ alkyl, C ₁₋₄ alkoxy or cyano, then R ² is H or C ₁₋₃ alkyl; and if R ² is -N(H)C(O)O-C ₁₋₄ alkyl, C ₁₋₄ alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting
25	of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl,
30	dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C ₁₋₄ alkyl, C ₁₋₄ alkoxy or cyano, then R ¹ is H or C ₁₋₃ alkyl.

- 44. A pharmaceutically acceptable formulation comprising a compound according to claim 1.
- 45. A method of treating depression, attention deficit hyperactivity disorder,
 obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders and sexual dysfunction comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
- 46. A method of treating sexual dysfunction comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
 - 47. A method of treating premature ejaculation comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
- 15 48. A compound or pharmaceutically acceptable salt or solvate thereof selected from the group consisting of
 - 3-(3-methylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - 3-(3-ethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - 3-(3-dimethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
- 20 3-[3-(ethyl-methyl-amino)-cyclopentyl]-1*H*-indole-5-carbonitrile;
 - 3-(3-diethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - 3-(3-pyrrolidin-1-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - 3-[3-(1,3-dihydro-isoindol-2-yl)-cyclopentyl]-1*H*-indole-5-carbonitrile;
 - 3-[3-(3,4-dihydro-1*H*-isoquinolin-2-yl)-cyclopentyl]-1*H*-indole-5-carbonitrile;
- 25 3-(3-penethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - 3-[3-(methyl-phenethyl-amino)-cyclopentyl]-1*H*-indole-5-carbonitrile;
 - 3-(3-morpholin-4-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - 3-[3-(benzyl-methyl-amino)-cyclopentyl]-1*H*-indole-5-carbonitrile;
 - 3-(3-benzylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
- 30 3-(3-piperidin-1-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - 3-(3-dipropylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - 3-(3-propylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;

```
1-methyl-3-(3-methylamino-cyclopentyl)-1H-indole-5-carbonitrile;
          3-(3-ethylamino-cyclopentyl)-1-methyl-1H-indole-5-carbonitrile;
          3-(3-benzylamino-cyclopentyl)-1-methyl-1H-indole-5-carbonitrile;
          1-methyl-3-(3-phenethylamino-cyclopentyl)-1H-indole-5-carbonitrile;
          3-(3-dimethylamino-cyclopentyl)-1-methyl-1H-indole-5-carbonitrile;
5
          3-[3-(ethyl-methyl-amino)-cyclopentyl]-1-methyl-1H-indole-5-carbonitrile;
          3-(3-diethylamino-cyclopentyl)-1-methyl-1H-indole-5-carbonitrile;
          1-methyl-3-(3-pyrrolidin-1-yl-cyclopentyl)-1H-indole-5-carbonitrile;
          1-methyl-3-(3-piperidin-1-yl-cyclopentyl)-1H-indole-5-carbonitrile;
          1-methyl-3-(3-morpholin-4-yl-cyclopentyl)-1H-indole-5-carbonitrile;
10
          3-[3-(benzyl-methyl-amino)-cyclopentyl]-1-methyl-1H-indole-5-carbonitrile;
          1-methyl-3-[3-(methyl-phenethyl-amino)-cyclopentyl]-1H-indole-5-carbonitrile;
           1-methyl-3-(3-propylamino-cyclopentyl)-1H-indole-5-carbonitrile;
           3-(3-dipropylamino-cyclopentyl)-1-methyl-1H-indole-5-carbonitrile;
           3-[3-(benzyl-methyl-amino)-cyclopentyl]-1-ethyl-1H-indole-5-carbonitrile;
15
           3-(3-dimethylamino-cyclopentyl)-1-ethyl-1H-indole-5-carbonitrile;
           3-(5-fluoro-1H-indol-3-yl)-cyclopenty]-dimethyl-amine;
           ethyl-[3-(5-fluoro-1H-indol-3-yl)-cyclopentyl]-methyl-amine;
           diethyl-[3-(5-fluoro-1H-indol-3-yl)-cyclopentyl]-amine;
           5-fluoro-3-(3-pyrrolidin-1-yl-cyclopentyl)-1H-indole;
20
           3-(4-fluoro-1H-indol-3-yl)-cyclopentyl-dimethyl-amine;
           3-(4-bromo-1H-indol-3-yl)-cyclopentyl-dimethyl-amine;
           3-(5-dhloro-1H-indol-3-yl)-cyclopentyl-dimethyl-amine;
           3-(5-bromo-1H-indol-3-yl)-cyclopentyl-dimethyl-amine;
           3-(5-iodo-1H-indol-3-yl)-cyclopentyl-dimethyl-amine;
25
           3-(6-fluoro-1H-indol-3-yl)-cyclopentyl-dimethyl-amine;
           3-(6-chloro-1H-indol-3-yl)-cyclopentyl-dimethyl-amine;
           3-(6-bromo-1H-indol-3-yl)-cyclopentyl-dimethyl-amine;
           3-(7-fluoro-1H-indol-3-yl)-cyclopentyl-dimethyl-amine;
           3-(7-chloro-1H-indol-3-yl)-cyclopentyl-dimethyl-amine;
 30
           3-(7-bromo-1H-indol-3-yl)-cyclopentyl-dimethyl-amine;
           (1S, 3R)-3-(3-dimethylaminocyclopentyl)-1H-indole-5-carbonitrile;
            (1S,3S)-3-(3-dimethylaminocyclopentyl)-1H-indole-5-carbonitrile;
```

68

```
(1R,3S)-3-(3-dimethylaminocyclopentyl)-1H-indole-5-carbonitrile;
(1R,3R)-3-(3-dimethylaminocyclopentyl)-1H-indole-5-carbonitrile;
(1S,3S)-3-(5-fluoro-1H-indol-3-yl)-cyclopentyl-dimethylamine;
(1R,3S)-3-(5-fluoro-1H-indol-3-yl)-cyclopentyl-dimethylamine;
(1R,3R)-3-(5-fluoro-1H-indol-3-yl)-cyclopentyl-dimethylamine;
(1S,3R)-3-(5-fluoro-1H-indol-3-yl)-cyclopentyl-dimethylamine;
(1S,3R)-3-(3-dimethylamino-cyclopentyl)-1-ethyl-1H-indole-5-carbonitrile;
(1S,3S)-3-(3-dimethylamino-cyclopentyl)-1-ethyl-1H-indole-5-carbonitrile;
(1R,3S)-3-(3-dimethylamino-cyclopentyl)-1-ethyl-1H-indole-5-carbonitrile;
(1S)-3-(3-amino-cyclopentyl)-1H-indole-5-carbonitrile;
(1S)-3-(3-amino-cyclopentyl)-1H-indole-5-carbonitrile; and
```